Corey Davis has joined H.C. Wainwright in equity research as a managing director, covering specialty pharmaceuticals.
Dr. Davis has 19 years of sell-side experience, covering specialty pharmaceutical companies, spending most of those years at JP Morgan and Jefferies. His therapeutic areas of focus include CNS-related disorders, such as multiple sclerosis, epilepsy, depression, bipolar disorder, pain and Alzheimer’s disease. He also specializes in dermatology, gastroenterology and ophthalmology.
In a statement, Mark Viklund, CEO of HCW, said Dr. Davis’ extensive experience in the sector and his reputation for providing highly analytical advice to investors will further enhance HCW’s ability to provide clients with superior service.
With the addition of Dr. Davis, HCW’s healthcare research team now includes eight analysts covering disciplines within biotechnology and specialty pharmaceuticals.
